By Sabela Ojea

Reckitt Benckiser Group PLC said Friday it is proposing to sell its E45 skincare brand and related sub-brands to Karo Pharma AB for an implied enterprise value of 200 million pounds ($268.2 million).

The consumer-goods company--which houses Dettol, Harpic and Durex among its brands--said E45 generated a combined net revenue of GBP43 million for the year ended Dec. 31, 2020.

"The proposed sale, if completed, would be another step forward in Reckitt's plan to actively manage its portfolio for higher growth," the London-listed company said.

The transaction is expected to be completed in the first quarter of 2022, it said.

Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix

(END) Dow Jones Newswires

December 24, 2021 02:31 ET (07:31 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Reckitt Benckiser (PK) (USOTC:RBGLY)
Historical Stock Chart
From Jan 2025 to Feb 2025 Click Here for more Reckitt Benckiser (PK) Charts.
Reckitt Benckiser (PK) (USOTC:RBGLY)
Historical Stock Chart
From Feb 2024 to Feb 2025 Click Here for more Reckitt Benckiser (PK) Charts.